https://www.biopharmawatch.com/news/MRNA/moderna-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T00:00:00.000Z Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026 https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-third-quarter-results-2026 BiopharmaWatch en 2026-10-28T00:00:00.000Z ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026 https://www.biopharmawatch.com/news/ALGN/align-technology-patent-infringement-case-angelalign BiopharmaWatch en 2026-10-17T01:11:00.000Z Align Technology Wins Significant Patent Infringement Case Against Angelalign at Unified Patent Court https://www.biopharmawatch.com/news/ANNX/annexon-reports-inducement-grants-new-employees-nasdaq-listing-rule-5635-20261016 BiopharmaWatch en 2026-10-16T21:34:00.000Z Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/IOVA/iovance-biotherapeutics-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261016 BiopharmaWatch en 2026-10-16T21:15:00.000Z Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-inducement-grants-new-employees BiopharmaWatch en 2026-10-16T21:00:00.000Z Actinium Pharmaceuticals Announces Inducement Grants to New Employees https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261016 BiopharmaWatch en 2026-10-16T20:20:00.000Z Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) https://www.biopharmawatch.com/news/SRRK/scholar-rock-reports-new-employee-inducement-grants-nasdaq-listing-rule-20261016 BiopharmaWatch en 2026-10-16T20:15:00.000Z Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261016 BiopharmaWatch en 2026-10-16T20:15:00.000Z Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/FDMT/4dmt-announces-new-employment-inducement-grants-20261016 BiopharmaWatch en 2026-10-16T20:05:00.000Z 4DMT Announces New Employment Inducement Grants https://www.biopharmawatch.com/news/KRRO/korro-bio-inducement-grants-nasdaq-rule-5635c4 BiopharmaWatch en 2026-10-16T20:05:00.000Z Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/VTRS/viatris-fda-approval-ryzumvi-presbyopia BiopharmaWatch en 2026-10-16T20:05:00.000Z Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia https://www.biopharmawatch.com/news/PRLD/prelude-therapeutics-chardan-healthcare-conference-2026 BiopharmaWatch en 2026-10-16T20:01:00.000Z Prelude Therapeutics to Participate in the Chardan Healthcare Conference https://www.biopharmawatch.com/news/ALC/fda-approves-alcon-brytly-eye-drops BiopharmaWatch en 2026-10-16T19:57:00.000Z FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes https://www.biopharmawatch.com/news/IRD/opus-genetics-fda-approval-phentolamine-presbyopia BiopharmaWatch en 2026-10-16T16:00:00.000Z Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia https://www.biopharmawatch.com/news/IBRX/immunitybio-phase-3-data-cystectomy-avoidance BiopharmaWatch en 2026-10-16T15:49:00.000Z ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors https://www.biopharmawatch.com/news/MBRX/moleculin-announces-reverse-stock-split-20261016 BiopharmaWatch en 2026-10-16T13:20:00.000Z Moleculin Announces Reverse Stock Split https://www.biopharmawatch.com/news/REVB/revelation-biosciences-reverse-stock-split-october-2026 BiopharmaWatch en 2026-10-16T13:00:00.000Z Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026 https://www.biopharmawatch.com/news/NTHI/neonc-neo100-child-improvement-compassionate-use BiopharmaWatch en 2026-10-16T12:56:00.000Z NeOnc’s Boldest Test Yet: Child’s Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone https://www.biopharmawatch.com/news/GEHC/ge-healthcare-end-tidal-control-software-study BiopharmaWatch en 2026-10-16T12:47:00.000Z Research conducted at University of Michigan published in Anesthesia & Analgesia Practice demonstrates GE HealthCare End-tidal Control software may help to reduce fresh gas flow https://www.biopharmawatch.com/news/IART/integra-lifesciences-ent-technologies-aao-hnsf-2026 BiopharmaWatch en 2026-10-16T12:39:00.000Z Integra LifeSciences to Highlight ENT and Instruments Portfolios and Sponsor New Clinical Research Presentations at AAO-HNSF 2026 Annual Meeting https://www.biopharmawatch.com/news/PPCB/propanc-prp-chemotherapy-resistant-pancreatic-cancer BiopharmaWatch en 2026-10-16T12:36:00.000Z Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-real-world-evidence-cah BiopharmaWatch en 2026-10-16T12:30:00.000Z Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-eanm-2026-atnm-400-presentations BiopharmaWatch en 2026-10-16T12:30:00.000Z Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-pre-esmo-panel-weei-inhibition BiopharmaWatch en 2026-10-16T12:30:00.000Z Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology https://www.biopharmawatch.com/news/ASND/transcon-cnp-positive-chmp-opinion-achondroplasia BiopharmaWatch en 2026-10-16T12:29:00.000Z Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children https://www.biopharmawatch.com/news/BMRA/biomerica-first-quarter-fiscal-2027-results BiopharmaWatch en 2026-10-16T12:19:00.000Z Biomerica Reports First Quarter Fiscal 2027 Financial Results https://www.biopharmawatch.com/news/RPRX/royalty-pharma-fourth-quarter-2026-dividend BiopharmaWatch en 2026-10-16T12:02:30.000Z Royalty Pharma declares fourth quarter 2026 dividend https://www.biopharmawatch.com/news/NTHI/neonc-reports-clinical-improvement-child-treated-neo100 BiopharmaWatch en 2026-10-16T12:00:32.000Z NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi https://www.biopharmawatch.com/news/AZTR/azitra-inc-announces-reverse-stock-split BiopharmaWatch en 2026-10-16T12:00:00.000Z Azitra, Inc. Announces Reverse Stock Split https://www.biopharmawatch.com/news/CRIS/curis-announces-private-placement-85-million-funding BiopharmaWatch en 2026-10-16T12:00:00.000Z Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors https://www.biopharmawatch.com/news/SCNI/scinai-immunotherapeutics-announces-closing-4-0-million-financing-through-private BiopharmaWatch en 2026-10-16T12:00:00.000Z Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-cfo-retirement-richard-lindahl BiopharmaWatch en 2026-10-16T11:50:00.000Z Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl https://www.biopharmawatch.com/news/ALEC/alector-pricing-underwritten-offering BiopharmaWatch en 2026-10-16T11:30:00.000Z Alector Announces Pricing of Underwritten Offering https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-sean-maenpaa-appointment BiopharmaWatch en 2026-10-16T11:30:00.000Z Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development https://www.biopharmawatch.com/news/IRWD/ironwood-pharmaceuticals-appoints-tammi-gaskins-ceo BiopharmaWatch en 2026-10-16T11:30:00.000Z Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer https://www.biopharmawatch.com/news/OGN/organon-positive-interim-phase-3-results-miu-della BiopharmaWatch en 2026-10-16T11:30:00.000Z Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting https://www.biopharmawatch.com/news/BBIO/bridgebio-pharma-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261016 BiopharmaWatch en 2026-10-16T11:30:00.000Z BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/REGN/libtayo-eu-approval-chmp-dosing-regimen BiopharmaWatch en 2026-10-16T11:00:00.000Z Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types https://www.biopharmawatch.com/news/TLSA/tiziana-doses-last-patient-phase-2-trial-alzheimers BiopharmaWatch en 2026-10-16T11:00:00.000Z Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease https://www.biopharmawatch.com/news/ADIL/adial-pharmaceuticals-appoints-david-rubenstein-chief-scientist BiopharmaWatch en 2026-10-16T11:00:00.000Z Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis https://www.biopharmawatch.com/news/GUTS/fractyl-health-revita-remains-1-study-results BiopharmaWatch en 2026-10-16T11:00:00.000Z Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-vopimetostat-esmo-2026 BiopharmaWatch en 2026-10-16T11:00:00.000Z Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026 https://www.biopharmawatch.com/news/IONS/tryngolza-olezarsen-eu-approval-recommendation BiopharmaWatch en 2026-10-16T10:45:00.000Z TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG) https://www.biopharmawatch.com/news/JNJ/chmp-recommends-approval-talvey-daratumumab-multiple-myeloma BiopharmaWatch en 2026-10-16T10:31:00.000Z CHMP recommends approval of Johnson & Johnson’s TALVEY®▼ (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myeloma https://www.biopharmawatch.com/news/HIT/health-in-tech-annual-meeting-2026 BiopharmaWatch en 2026-10-16T10:30:00.000Z Health In Tech to Host Annual Meeting of Stockholders https://www.biopharmawatch.com/news/OMER/omeros-chmp-negative-opinion-narsoplimab-ta-tma BiopharmaWatch en 2026-10-16T10:19:00.000Z Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA https://www.biopharmawatch.com/news/ESLA/estrella-immunopharma-first-patient-eb103-star-light-1 BiopharmaWatch en 2026-10-15T22:45:00.000Z Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase